SCHEMBL4156926

SCHEMBL4156926

CCOC(=O)c1cn(OC)c2ccc(I)cc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.53
PTPN1 P18031 1/20 0.45
KMT2A Q03164 3/20 0.45
HPGD P15428 4/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
THRB P10828 1/20 0.43
MAP2K2 P36507 1/20 0.43
MAP2K1 Q02750 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 5/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
TDP1 Q9NUW8 1/20 0.41
NPC1 O15118 1/20 0.41
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4142387 0.85 LMNA (0.55) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL1429954 0.84 LMNA (0.74) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL4144523 0.83 ALDH1A1 (0.48) LMNAPTPN1KMT2AHPGDMAP2K2
SCHEMBL7941010 0.82 TDP1 (0.53) LMNAKMT2AHPGDMAPTMEN1
SCHEMBL3001658 0.82 LMNA (0.52) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL4141613 0.82 LMNA (0.52) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL3294927 0.82 LMNA (0.52) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL4141591 0.82 LMNA (0.61) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL1431209 0.81 LMNA (0.57) LMNAPTPN1KMT2AHPGDMAPT
SCHEMBL3004121 0.81 LMNA (0.60) LMNAPTPN1KMT2AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170791-A1 MACROLONES GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION 2009-07-02 US disclosed
US-20090170791-A1 MACROLONES GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION 2009-07-02 US disclosed
US-20090170791-A1 MACROLONES GLAXO SMITH KLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O A CORPORATION 2009-07-02 US disclosed
US-20090062218-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2009-03-05 US disclosed
EP-1945652-A1 MACROLONES GLAXO GROUP LIMITED (GB) 2008-07-23 EP disclosed
EP-1824871-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2007-08-29 EP disclosed
WO-2007054296-A1 MACROLONES GLAXO GROUP LIMITED (GB) 2007-05-18 WO disclosed
WO-2006050940-A1 MACROLONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062218-A1 MACROLONE COMPOUNDS CYP51A1, MRPL21, MYD88 LMNA 1055/4885PTPN1 1781/4885KMT2A 3931/4885
US-20090170791-A1 MACROLONES CYP51A1, MRPL21, LSS LMNA 1071/4885PTPN1 2213/4885KMT2A 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.